KLOW

What KLOW is

KLOW is a catalogue peptide blend combining four distinct bioactive compounds: GHK-Cu (glycyl-L-histidyl-L-lysine copper complex), BPC-157 (Body Protective Compound-157), TB-500 (a synthetic fragment of Thymosin Beta-4), and KPV (Lys-Pro-Val, the C-terminal tripeptide of α-melanocyte-stimulating hormone). Each component belongs to a different peptide class and was independently identified through decades of biochemical and preclinical investigation [1, 2, 3, 4]. GHK-Cu is a naturally occurring human tripeptide first identified in plasma; its circulating levels are known to decline with age, which has motivated research into its roles in skin remodeling and tissue repair ^[1]. BPC-157 is a synthetic pentadecapeptide derived from a protein found in gastric juice ^[2]. TB-500 corresponds to the actin-binding active region of Thymosin Beta-4, a 43-amino-acid protein expressed in virtually all nucleated cells ^[3]. KPV was isolated as the three C-terminal residues of α-MSH and was found to retain much of the parent molecule's anti-inflammatory signaling activity ^[4].

The KLOW formulation itself is a supplier-assembled blend designed to place these four research references into a single combined material for laboratory investigation ^[5]. Because the individual components operate through complementary but mechanistically distinct pathways—copper-mediated gene regulation, angiogenic growth-factor signaling, actin cytoskeleton reorganization, and NF-κB pathway modulation—the blend is categorized within the Skin & Anti-Aging research class. It is important to note that the KLOW combination as a whole has not been the subject of controlled clinical trials; all clinical and mechanistic evidence cited in the literature refers to the constituent peptides tested in isolation ^[5].

What it is being researched for

1. Skin collagen and elastin synthesis

GHK-Cu, the primary skin-active component of KLOW, has been extensively studied for its ability to modulate the production of collagen, elastin, and glycosaminoglycans in dermal fibroblasts ^[1]. In vitro work demonstrated that GHK-Cu incubated with human adult dermal fibroblasts increased production of both elastin and collagen in a concentration-responsive manner ^[6]. At the gene-expression level, studies measuring mRNA for MMP1, MMP2, TIMP1, and TIMP2 alongside colorimetric collagen and elastin assays in human dermal fibroblast cultures have mapped the dual regulatory role of the peptide on matrix turnover ^[6]. GHK-Cu performs an unusual dual action: it upregulates the matrix metalloproteinases that clear damaged collagen while simultaneously upregulating tissue inhibitors (TIMPs) that protect newly formed collagen ^[7]. Separately, research on collagen peptides more broadly has confirmed that exposure to small collagen-derived peptides increases expression of COL1A1, ELN, and versican (VCAN) genes in human dermal fibroblasts, consistent with the fibroblast-activating signals proposed for GHK-Cu ^[8].

2. Wound healing and tissue remodeling

GHK-Cu has a documented history of study in wound healing contexts. Controlled studies on aged skin showed that it can tighten skin, improve elasticity and firmness, reduce fine lines and photodamage ^[1]. A randomized placebo-controlled study in diabetic patients with plantar ulcers found that GHK-Cu significantly improved wound closure percentage and rate ^[9]. BPC-157 has also been investigated in wound-healing models: early rat studies examining skin incisional wounds, colon anastomoses, and angiogenesis via synthetic sponge implantation all demonstrated significantly better outcomes in BPC-157-treated animals relative to controls, with effects observed across multiple application routes ^[10]. In preclinical models, BPC-157 supported wound healing in esophageal, gastrointestinal, and dermal tissue in both acute and chronic injury paradigms ^[2]. TB-500, by promoting actin-dependent cell migration of fibroblasts, keratinocytes, and endothelial cells into injury sites, has been shown in rat wound models to increase re-epithelialization and wound contraction alongside increased collagen deposition ^[3].

3. Tendon, ligament, and musculoskeletal soft-tissue repair

BPC-157 has been most extensively studied for its preclinical effects on hypovascular and hypocellular soft tissues such as tendons and ligaments, which are notoriously slow to heal due to limited blood supply and cellular turnover ^[2]. A systematic review published in a peer-reviewed journal identified that all studies reviewed to date have demonstrated consistently positive and prompt healing effects for various injury types in these tissues, including traumatic and systemic injuries ^[11]. BPC-157 activates overlapping pathways—notably VEGFR2 and nitric oxide synthesis via the Akt-eNOS axis—promoting angiogenesis, fibroblast activity, and neuromuscular stabilization ^[2]. TB-500 complements this research area through its role in actin polymerization: by maintaining a reserve of polymerization-ready G-actin monomers, TB-500 enables rapid cell migration to injury sites in tendons and connective tissues ^[3]. Despite this broad preclinical support, human data for both BPC-157 and TB-500 in tendon and musculoskeletal applications remain extremely limited ^[2].

4. Inflammatory signaling modulation

KPV, the C-terminal tripeptide of α-MSH, is the primary anti-inflammatory component of the KLOW blend. Research has established that nanomolar concentrations of KPV inhibit the activation of NF-κB and MAP kinase inflammatory signaling pathways, and reduce pro-inflammatory cytokine secretion in human intestinal epithelial cells and immune cells ^[4]. KPV exerts its effects at least in part via the PepT1 di/tripeptide transporter expressed in immune and intestinal epithelial cells ^[4]. In murine colitis models, KPV treatment led to significantly reduced inflammatory infiltrates and earlier recovery as measured by histology and myeloperoxidase activity ^[12]. Alpha-MSH and its C-terminal tripeptide KPV have demonstrated anti-inflammatory activity across multiple animal models of inflammation including contact dermatitis, cutaneous vasculitis, inflammatory bowel disease, and asthma, suggesting broad applicability of this signaling pathway ^[13]. TB-500 has also shown anti-inflammatory properties through NF-κB suppression and by shifting macrophage polarization from the pro-inflammatory M1 phenotype toward the regenerative M2 phenotype ^[3].

5. Gastrointestinal barrier and gut health

Two of the KLOW components—KPV and BPC-157—have been studied independently for effects on the gastrointestinal tract. KPV reduced the incidence of experimentally induced colitis (DSS- and TNBS-induced) in mice when added to drinking water, with reductions in pro-inflammatory cytokine expression including IL-1β, IL-6, TNF-α, and IFN-γ ^[4]. The mechanism appears to involve KPV's uptake via the PepT1 transporter in both intestinal epithelial cells and lamina propria macrophages ^[4]. BPC-157, derived from a gastric protein sequence, has shown activity in supporting wound healing across the gastrointestinal tract in animal studies covering the esophagus, stomach, and duodenum ^[2]. These observations are considered preclinical; no controlled human trials have examined the gastrointestinal effects of the KLOW combination ^[5].

6. Angiogenesis and microcirculation

Angiogenesis—the formation of new blood vessels—is a research area where multiple KLOW components have shown activity in preclinical models. GHK-Cu promotes angiogenesis and was shown to attract capillary cells and macrophages to repair sites while supporting new blood flow ^[1]. BPC-157 activates VEGF and nitric oxide signaling pathways, with isolated rat aorta experiments demonstrating endothelium-dependent, nitric oxide-mediated vasodilation ^[2]. TB-500 promotes angiogenesis through its role in endothelial cell migration: actin regulation is central to the formation of new vasculature, and TB-500's sequestration of G-actin supports the cytoskeletal reorganization required for endothelial cell protrusion and vessel formation ^[3]. In older rodent models, where angiogenesis is naturally reduced, Thymosin Beta-4 (the parent protein of TB-500) was reported to promote angiogenesis and wound repair, suggesting potential relevance to age-related declines in vascular regeneration ^[3].

7. Photoaged and aging skin parameters

Clinical research on GHK-Cu—the dominant skin-active component of KLOW by mass—has specifically examined parameters of photoaged and intrinsically aged skin. A 12-week controlled trial in 71 women with mild to advanced photoaging reported significant increases in skin density and reductions in wrinkle volume using GHK-Cu formulations ^[9]. A separate randomized, double-blind clinical trial in 40 women aged 40–65 using GHK-Cu encapsulated in a lipid-based nano-carrier demonstrated a 55.8% reduction in wrinkle volume and a 32.8% reduction in wrinkle depth versus control ^[6]. An IRB-approved clinical study conducted at McGill University evaluated skin collagen density by high-resolution dermal ultrasound in 21 subjects after three months of GHK-Cu gel application, finding an average 28% increase in subdermal echogenic density, with the top quartile of participants averaging 51% improvement ^[14]. A Phase 2 randomized clinical trial registered on ClinicalTrials.gov (NCT07437586) is currently investigating topical GHK-Cu gel for acute skin wound healing and re-epithelialization, reflecting ongoing formal clinical interest in this peptide's dermal effects ^[15].

How it is thought to work

Each of the four components in KLOW operates through a distinct molecular mechanism. GHK-Cu binds copper ions and, once internalized by cells, modulates gene expression at the level of TGF-β, SMAD, MMP, and TIMP signaling cascades, resulting in upregulated production of collagen, elastin, and glycosaminoglycans in dermal fibroblasts [1, 6]. It simultaneously triggers antioxidant enzyme expression and has been shown to block ferritin-mediated release of oxidized iron, protecting tissues from oxidative stress ^[1]. BPC-157 activates a signaling chain running from VEGFR2 through Akt to eNOS, which produces nitric oxide—a molecule that dilates blood vessels and supports tissue repair—while also engaging ERK1/2 signaling to facilitate endothelial and muscle repair and exert anti-inflammatory effects ^[2]. Preclinical models also indicate BPC-157 promotes growth hormone receptor expression and reduces inflammatory cytokines ^[2].

TB-500, the synthetic fragment of Thymosin Beta-4, works by sequestering G-actin (globular actin monomers), preventing premature polymerization and maintaining a ready pool for rapid cytoskeletal reorganization ^[3]. This actin-sequestering function is the rate-limiting driver of cell migration—the process by which fibroblasts, keratinocytes, and endothelial cells travel to sites of injury for repair—making TB-500 functionally upstream of wound healing and angiogenesis ^[3]. KPV, the C-terminal tripeptide of α-MSH, is taken up via the PepT1 transporter in intestinal epithelial and immune cells, where it inhibits NF-κB and MAP kinase inflammatory signaling pathways and reduces secretion of pro-inflammatory cytokines such as IL-1β, IL-6, and TNF-α ^[4]. Together, these four mechanisms—gene-level matrix regulation, nitric oxide-driven angiogenesis, actin-mediated cell migration, and cytokine pathway modulation—are considered complementary in preclinical models, though their combined interaction in a single formulation has not been characterized in controlled studies ^[5].

Where the evidence stands

The evidence base for KLOW's constituent peptides is asymmetric across species and study design, and must be understood at the level of each individual component rather than the blend as a whole ^[5]. GHK-Cu has the strongest human evidence within the blend: multiple randomized controlled trials of topical GHK-Cu formulations have reported improvements in skin density, wrinkle depth, wrinkle volume, and elasticity in women with photoaged skin [6, 9, 14]. A Phase 2 randomized clinical trial (NCT07437586) is currently underway to evaluate topical GHK-Cu for acute wound healing ^[15]. BPC-157, while demonstrating consistently positive results across a large library of animal models for musculoskeletal repair and gastrointestinal healing, has been evaluated in only three small human pilot studies covering intra-articular knee pain, interstitial cystitis, and intravenous safety/pharmacokinetics; no large-scale randomized controlled trials have been completed ^[2]. The FDA has also determined BPC-157 to be unsafe for use in compounded medications, reflecting regulatory concern about the limited human safety data ^[2].

TB-500 (as a distinct synthetic fragment) has no published human clinical data; its parent protein, Thymosin Beta-4, progressed to a human trial under the investigational name RGN-352 in a different indication, but the TB-500 fragment itself remains at the preclinical stage ^[3]. KPV's human evidence is limited to in vitro studies in human intestinal epithelial cells and immune cell lines, with in vivo data confined to murine colitis models [4, 12]. No published studies have evaluated the KLOW combination in humans, and the synergistic or antagonistic interactions among the four components at the tissue level are unknown ^[5]. Key limitations across all components include small sample sizes in available human studies, frequent industry or research-group conflicts of interest, and the gap between robust rodent pharmacology and validated human efficacy—particularly for BPC-157 and TB-500.

Frequently asked questions

What is KLOW peptide and what is it made of?

KLOW is a research-grade peptide blend combining four independently studied compounds: GHK-Cu (a copper-binding tripeptide), BPC-157 (a synthetic pentadecapeptide derived from gastric proteins), TB-500 (a synthetic fragment of Thymosin Beta-4), and KPV (the C-terminal tripeptide of alpha-melanocyte-stimulating hormone). Each component has its own distinct research history and mechanism of action. The KLOW combination as a whole has not been the subject of controlled clinical trials.

What is KLOW peptide studied for?

In research settings, KLOW is studied for its potential involvement in skin collagen and elastin synthesis, soft-tissue and wound healing, musculoskeletal repair, inflammatory signaling modulation, and gastrointestinal barrier function. These research areas reflect the combined properties of its four components studied individually. Human clinical evidence is currently strongest for GHK-Cu in skin applications and remains largely preclinical for BPC-157, TB-500, and KPV.

Is KLOW the same as GLOW peptide?

KLOW and GLOW are related but distinct peptide blends. Both typically contain GHK-Cu, BPC-157, and TB-500. KLOW is distinguished by the addition of KPV, a tripeptide derived from alpha-MSH that is studied for its anti-inflammatory and gut health properties. The inclusion of KPV is the primary compositional difference between the two formulations.

What does GHK-Cu do in the KLOW blend?

GHK-Cu is the skin-focused anchor of the KLOW blend. It binds copper ions and modulates gene expression to stimulate collagen and elastin production, promote angiogenesis, and reduce oxidative stress in dermal tissues. It also performs a dual regulatory function on matrix metalloproteinases—upregulating enzymes that clear damaged collagen while protecting newly synthesized collagen via tissue inhibitors. It has the strongest human clinical evidence of the four components.

Has KLOW peptide been tested in human clinical trials?

The KLOW combination as a formulation has not been tested in controlled human clinical trials. Its individual components have varying levels of human evidence: GHK-Cu has multiple randomized controlled topical skin trials, and a Phase 2 wound-healing trial is currently registered on ClinicalTrials.gov. BPC-157 has only three small pilot human studies. TB-500 as a distinct fragment has no published human data. KPV's human evidence comes from in vitro studies only.

What is BPC-157 and why is it included in KLOW?

BPC-157 is a synthetic pentadecapeptide derived from a protein found in gastric juice. It is included in KLOW because of its preclinical evidence supporting tissue repair, angiogenesis (via VEGFR2 and nitric oxide pathways), fibroblast activation, and gastrointestinal healing across a wide range of animal models. It is considered a regenerative complement to GHK-Cu's collagen-focused skin activity. All current BPC-157 evidence in musculoskeletal applications is preclinical.

What is KPV peptide and what makes it different from the other components?

KPV (Lys-Pro-Val) is the three C-terminal amino acids of alpha-melanocyte-stimulating hormone (alpha-MSH). Unlike the other three KLOW components, which primarily target structural repair and matrix remodeling, KPV is studied specifically for its anti-inflammatory signaling properties. Research shows it inhibits NF-κB and MAP kinase pathways and reduces pro-inflammatory cytokine secretion, and it is taken up via the PepT1 transporter in intestinal and immune cells.

What is TB-500 and how does it differ from Thymosin Beta-4?

TB-500 is a synthetic peptide corresponding to the active actin-binding region of Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino-acid protein found in virtually all nucleated cells. TB-500 retains the segment most responsible for G-actin sequestration and cell migration, making it easier to synthesize at research-grade purity than the full Tβ4 protein. The parent protein Thymosin Beta-4 has progressed to human investigation in some contexts, but the TB-500 fragment itself has no published human clinical data.

Is KLOW peptide approved by Health Canada or the FDA?

No. KLOW is not approved as a therapeutic drug by Health Canada, the FDA, or any comparable regulatory body. It is classified as a research compound intended strictly for laboratory investigation. Notably, the FDA has determined that BPC-157, one of the four components, is unsafe for use in compounded medications, reflecting regulatory concern about incomplete human safety data. KLOW products are not for human or veterinary use.

What are the limitations of the current research on KLOW?

The primary limitations include the complete absence of controlled clinical trials on the KLOW combination itself, the largely preclinical (animal and cell-based) evidence base for BPC-157, TB-500, and KPV, and small sample sizes in the available human studies for GHK-Cu. Unknown interactions among the four co-administered components represent an additional scientific gap. Regulatory restrictions on BPC-157 in compounded products further underscore the need for rigorous, independent human trials before any clinical conclusions can be drawn.

Glossary

GHK-Cu

Glycyl-L-histidyl-L-lysine copper complex; a naturally occurring human tripeptide that binds copper(II) ions and is studied for its roles in collagen synthesis, skin remodeling, angiogenesis, and antioxidant gene regulation.

BPC-157

Body Protective Compound-157; a synthetic 15-amino-acid (pentadecapeptide) sequence derived from a gastric protein, studied preclinically for tissue repair, angiogenesis, and gastrointestinal healing.

TB-500

A synthetic peptide fragment corresponding to the actin-binding active region of Thymosin Beta-4, studied for its role in G-actin sequestration, cell migration, wound healing, and anti-inflammatory effects in preclinical models.

KPV

Lys-Pro-Val; the C-terminal tripeptide (residues 11–13) of alpha-melanocyte-stimulating hormone (α-MSH), studied for its ability to inhibit NF-κB and MAP kinase inflammatory signaling pathways.

Matrix metalloproteinase (MMP)

A family of enzymes responsible for breaking down extracellular matrix proteins such as damaged collagen; their activity is regulated by tissue inhibitors of metalloproteinases (TIMPs), and GHK-Cu is studied for modulating this balance.

Angiogenesis

The biological process by which new blood vessels grow from pre-existing vasculature; studied in the context of KLOW because GHK-Cu, BPC-157, and TB-500 have each shown angiogenic activity in preclinical models.

NF-κB

Nuclear factor kappa-light-chain-enhancer of activated B cells; a key transcription factor regulating the expression of pro-inflammatory cytokines, and a signaling target of KPV's anti-inflammatory mechanism.

Matrikine

A peptide fragment released by partial proteolytic digestion of extracellular matrix proteins such as collagen; GHK is classified as a matrikine and is considered a biological signaling molecule that regulates wound healing.

References

1. The human tri-peptide GHK and tissue remodeling — Journal of Peptide Science / PubMed
2. From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management — International Journal of Molecular Sciences
3. A Tobacco-Derived Thymosin β4 Concatemer Promotes Cell Proliferation and Wound Healing in Mice — PLOS ONE / PubMed Central
4. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation — Gastroenterology / PubMed
5. KLOW Research Peptide Blend – product and category information — Aminoclub US (supplier catalogue)
6. Effects of GHK-Cu on MMP and TIMP Expression, Collagen and Elastin Production and Facial Wrinkle Parameters — Journal of Aging Science
7. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data — Cosmetics / PubMed Central
8. Collagen peptides affect collagen synthesis and the expression of collagen, elastin, and versican genes in cultured human dermal fibroblasts — PLOS ONE / PubMed Central
9. BPC-157 and GHK-Cu in Wound Healing and Tissue Repair: A Review of Clinical Efficacy and Safety — ResearchGate / peer-reviewed review
10. BPC 157's effect on healing — Journal of Physiology / PubMed
11. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing — Cell and Tissue Research / PubMed
12. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease — Inflammatory Bowel Diseases / PubMed
13. alpha-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs — Annals of the Rheumatic Diseases / PubMed
14. Epigenetic mechanisms activated by GHK-Cu increase skin collagen density in clinical trial — EurekAlert / Yuvan Research clinical study press release
15. Topical GHK-Cu Gel for Acute Skin Wound Healing (NCT07437586) — ClinicalTrials.gov